SecSonar.com

Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Gyre Therapeutics, Inc. (GYRE) is a Biotechnology company based in US with a market capitalization of $572.7M. Revenue grew 10.2% year-over-year and free cash flow was negative at -$180K. This page tracks GYRE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 579 employees · IPO Apr 12, 2006

Valuation

Valuation & price

$6.55 · as of May 17, 2026 · -26.2% vs 52w high

134.4

P/E ratio

Latest-FY diluted EPS

5.40

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$8.76$7.22$5.69Jul 25Dec 25Jul 26Jul 7, 25$7.62Jul 9, 25$8.00Jul 11, 25$7.49Jul 15, 25$7.16Jul 17, 25$7.39Jul 21, 25$7.10Jul 23, 25$7.57Jul 25, 25$7.64Jul 29, 25$7.30Jul 31, 25$7.05Aug 4, 25$7.02Aug 6, 25$7.02Aug 11, 25$7.07Aug 13, 25$8.21Aug 15, 25$8.14Aug 19, 25$7.53Aug 21, 25$7.55Aug 25, 25$8.20Aug 27, 25$8.11Aug 29, 25$7.74Sep 3, 25$8.08Sep 5, 25$7.69Sep 9, 25$7.67Sep 11, 25$8.12Sep 16, 25$7.59Sep 18, 25$7.69Sep 22, 25$7.47Sep 24, 25$7.37Sep 26, 25$7.16Sep 30, 25$7.46Oct 2, 25$7.52Oct 6, 25$7.34Oct 8, 25$7.30Oct 10, 25$7.96Oct 14, 25$8.01Oct 16, 25$8.74Oct 21, 25$8.32Oct 23, 25$8.23Oct 27, 25$8.02Oct 29, 25$7.54Oct 31, 25$7.75Nov 4, 25$7.25Nov 6, 25$7.34Nov 10, 25$7.92Nov 12, 25$8.34Nov 14, 25$7.99Nov 18, 25$7.67Nov 20, 25$7.49Nov 25, 25$7.72Nov 28, 25$7.75Dec 2, 25$7.58Dec 4, 25$7.90Dec 8, 25$8.16Dec 10, 25$8.46Dec 12, 25$7.69Dec 16, 25$7.58Dec 18, 25$7.35Dec 22, 25$7.19Dec 24, 25$7.19Dec 29, 25$7.16Jan 2, 26$6.81Jan 6, 26$6.97Jan 8, 26$7.57Jan 12, 26$7.70Jan 14, 26$7.69Jan 16, 26$7.68Jan 21, 26$8.30Jan 23, 26$7.85Jan 27, 26$8.09Jan 29, 26$8.21Feb 2, 26$8.21Feb 4, 26$7.77Feb 9, 26$7.82Feb 11, 26$7.85Feb 13, 26$8.02Feb 18, 26$8.21Feb 20, 26$8.28Feb 24, 26$8.40Feb 26, 26$8.52Mar 2, 26$8.76Mar 4, 26$8.28Mar 6, 26$7.71Mar 10, 26$8.12Mar 12, 26$7.81Mar 17, 26$7.65Mar 19, 26$6.80Mar 23, 26$7.04Mar 25, 26$7.18Mar 27, 26$6.78Mar 31, 26$6.97Apr 2, 26$7.12Apr 7, 26$7.12Apr 9, 26$7.24Apr 13, 26$7.69Apr 15, 26$8.02Apr 17, 26$8.10Apr 22, 26$7.73Apr 24, 26$7.44Apr 28, 26$7.67Apr 30, 26$7.68May 4, 26$7.92May 6, 26$8.04May 8, 26$7.47May 12, 26$7.30May 14, 26$7.00May 18, 26$6.44May 20, 26$6.04May 22, 26$6.06May 28, 26$5.74Jun 1, 26$5.81Jun 3, 26$5.69Jun 5, 26$6.29Jun 9, 26$6.13Jun 11, 26$6.06Jun 15, 26$5.86Jun 17, 26$6.08Jun 22, 26$6.13Jun 24, 26$6.48Jun 26, 26$6.29Jul 2, 26$7.34
$5.5652-week range$8.87
Loading valuation history…

Fundamentals

Key fundamentals

$572.7M

Market cap

10.2%

Revenue growth (YoY)

95.3%

Gross margin

-$180K

Free cash flow (USD)

-$51.5M

Net debt

Net cash position

5.0%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$399.0KFY 2017$1.0MFY 2018$6.0KFY 2019$0.00FY 2020$20.9MFY 2021$7.3MFY 2022$102.3MFY 2023$113.5MFY 2024$105.8MFY 2025$116.6M
$399K$116.6M

Free cash flow by year

2016 → 2025

FY 2016$-18.9MFY 2017$-20.0MFY 2018$-28.9MFY 2019$-43.7MFY 2020$-55.3MFY 2021$-84.6MFY 2022$5.7MFY 2023$17.3MFY 2024$-6.8MFY 2025$-180.0K
-$18.9M-$180K

Gross margin by year

2021 → 2025

FY 2021-4.5%FY 202295.3%FY 202395.9%FY 202496.3%FY 202595.3%
-4.5%95.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

9

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $69KYe Weiguo · Chief Operating Officer · $68.7KJun 22, 2026Filing
  • FinancingSecurities RegistrationJun 22, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 16, 2026Filing
  • Insider sellInsider Sell $17KYe Weiguo · Chief Operating Officer · $17.3KJun 15, 2026Filing
  • Insider sellInsider Sell $129KYe Weiguo · Chief Operating Officer · $128.9KJun 11, 2026Filing
  • Insider sellInsider Sell $219KYe Weiguo · Chief Operating Officer · $218.6KJun 8, 2026Filing
  • 8-K eventForward-Looking StatementsJun 2, 2026Filing
  • Insider sellInsider Sell $46KYe Weiguo · Chief Operating Officer · $45.7KMay 27, 2026Filing
  • Insider sellInsider Sell $137KYe Weiguo · Chief Operating Officer · $136.7KMay 22, 2026Filing
  • Insider sellInsider Sell $59KYe Weiguo · Chief Operating Officer · $59.4KMay 20, 2026Filing

Questions

Frequently asked questions

What is Gyre Therapeutics, Inc.'s market cap?

Gyre Therapeutics, Inc. (GYRE) has a market capitalization of $572.7M.

What is GYRE's P/E ratio?

GYRE trades at a price-to-earnings ratio of 134.4, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is GYRE's price-to-book (P/B) ratio?

GYRE trades at 5.40 times book value per share.

Are insiders buying GYRE stock?

SEC Form 4 filings show no open-market insider buys at Gyre Therapeutics, Inc. in the last 90 days (9 sells).

Same arena

Related companies in Biotechnology

ARVN

Arvinas, Inc.

$572M

VALN

Valneva SE

$563.3M

CTMX

CytomX Therapeutics, Inc.

$582.2M

RIGL

Rigel Pharmaceuticals, Inc.

$562.1M

MDXG

MiMedx Group, Inc.

$553.3M

CBIO

Crescent Biopharma, Inc.

$598.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.